Literature DB >> 15638969

Dual-probe 24-hour ambulatory pH monitoring for diagnosis of laryngopharyngeal reflux.

W J Issing1, P D Karkos, K Perreas, C Folwaczny, O Reichel.   

Abstract

BACKGROUND: Patients with gastroesophageal reflux disease may suffer from a variety of symptoms from the upper aerodigestive tract. The objective of this study was to determine the impact of dual-probe 24-hr pH monitoring in the diagnosis of reflux-related otolaryngological disorders.
METHODS: Twenty-two patients with symptoms such as chronic cough, globus pharyngeus, heartburn, dysphonia and burning sensation of the tongue underwent a complete ear, nose and throat examination, 24-hr dual-probe pH monitoring, and oesophago-gastro-duodenoscopy.
RESULTS: pH monitoring revealed gastroesophageal (distal) reflux in all patients and pharyngeal (proximal) reflux in 21 patients. Treatment consisted of a proton pump inhibitor (esomeprazole). Within 4 weeks 68 per cent of patients had no laryngopharyngeal symptoms; within 8 weeks 95 per cent of patients were symptom-free.
CONCLUSIONS: Patients with atypical reflux symptoms such as hoarseness, globus sensation or throat-clearing responded well to anti-reflux treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15638969     DOI: 10.1258/0022215042703660

Source DB:  PubMed          Journal:  J Laryngol Otol        ISSN: 0022-2151            Impact factor:   1.469


  10 in total

Review 1.  Globus pharyngeus: a review of its etiology, diagnosis and treatment.

Authors:  Bong Eun Lee; Gwang Ha Kim
Journal:  World J Gastroenterol       Date:  2012-05-28       Impact factor: 5.742

2.  Pharyngeal pH monitoring better predicts a successful outcome for extraesophageal reflux symptoms after antireflux surgery.

Authors:  Stephanie G Worrell; Steven R DeMeester; Christina L Greene; Daniel S Oh; Jeffrey A Hagen
Journal:  Surg Endosc       Date:  2013-07-09       Impact factor: 4.584

3.  Clinical manifestations and role of proton pump inhibitors in the management of laryngopharyngeal reflux.

Authors:  Suhail Amin Patigaroo; S F Hashmi; Syed Abrar Hasan; M R Ajmal; Nazia Mehfooz
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2011-04-30

4.  [Repeated dual-probe pH monitoring as a diagnostic tool to control therapy for laryngopharyngeal reflux].

Authors:  O Reichel; F Durst; G Rasp; A Berghaus
Journal:  HNO       Date:  2007-10       Impact factor: 1.284

Review 5.  Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults.

Authors:  Anne B Chang; Toby J Lasserson; Justin Gaffney; Frances L Connor; Luke A Garske
Journal:  Cochrane Database Syst Rev       Date:  2011-01-19

6.  Proximal acid reflux treated by fundoplication predicts a good outcome for chronic cough attributable to gastro-oesophageal reflux disease.

Authors:  J Kirkby-Bott; E Jones; S Perring; S W Hosking
Journal:  Langenbecks Arch Surg       Date:  2010-11-11       Impact factor: 3.445

7.  Combined Dual Channel Impedance/pH-metry in Patients With Suspected Laryngopharyngeal Reflux.

Authors:  Bong Eun Lee; Gwang Ha Kim; Dong Yup Ryu; Dong Uk Kim; Jae Hoon Cheong; Dong Gun Lee; Geun Am Song
Journal:  J Neurogastroenterol Motil       Date:  2010-04-27       Impact factor: 4.924

8.  Laryngopharyngeal reflux: Current opinion.

Authors:  K K Handa
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2005-07

9.  Software improvement for evaluation of laryngopharyngeal pH testing (Restech) - a comparison between DataView 3 and 4.

Authors:  Dolores Thea Müller; Elena Schulte; Benjamin Babic; Laura Knepper; Claudia Fuchs; Wolfgang Schröder; Christiane J Bruns; Jessica M Leers; Hans Friedrich Fuchs
Journal:  World J Gastrointest Surg       Date:  2020-05-27

10.  Treatment of laryngopharyngeal reflux disease: A systematic review.

Authors:  Jerome R Lechien; Francois Mouawad; Maria R Barillari; Andrea Nacci; Seyyedeh Maryam Khoddami; Necati Enver; Sampath Kumar Raghunandhan; Christian Calvo-Henriquez; Young-Gyu Eun; Sven Saussez
Journal:  World J Clin Cases       Date:  2019-10-06       Impact factor: 1.337

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.